Platinum open access journal
pISSN 2466-0493 eISSN 2466-054X
Indexed in MEDLINE, SCIE, Scopus, DOAJ and more
    Korean J Urol. 2006 Sep;47(9):1001-1006. Korean.
    Published online Sep 30, 2006.
    https://doi.org/10.4111/kju.2006.47.9.1001
    Copyright © 2006 The Korean Urological Association
    Original Article

    Drug Interaction Study of Vardenafil 20mg and Doxazosin 4mg or Tamsulosin 0.2mg in Patients with Benign Prostatic Hyperplasia and Erectile Dysfunction to Evaluate Changes in Blood Pressure

    Shin Young Lee, Sae-Chul Kim, and Hyun Woo Kim1
      • Department of Urology, Chung-Ang University College of Medicine, Seoul, Korea.
      • 1Department of Urology, The Catholic University of Korea College of Medicine, Seoul, Korea.
    • Corresponding author (Email: saeckim@unitel.co.kr )
    Received May 03, 2006; Accepted August 08, 2006.

    Abstract

    Purpose

    This study aimed at evaluating the expected additive blood pressure (BP) lowering effect of vardenafil when administered in the background of chronic α1-blocker therapy.

    Materials and Methods

    Patients (n=90) with symptomatic benign prostatic hypertrophy (BPH) and erectile dysfunction (ED) took vardenafil 20mg in the morning following repeated doxazosin gastrointestinal therapeutic system (GITS) 4mg (n=60) or tamsulosin 0.2mg (n=30) HS a day for 30 days. The standing and sitting BP at baseline, before taking the vardenafil and 30 minutes and 1 hour post vardenafil were measured 3 consecutive times. The data were analyzed by Student's t-test (paired), repeated measures of two-way ANOVA, chi-square tests and Pearson correlation analysis.

    Results

    Doxazosin produced a significant reduction in systolic/diastolic BP (-12.3/-6.7mmHg), but tamsulosin did not. In the doxazosin group, the average reductions in BP from baseline (-24.7/-15.8mmHg) were significantly higher than that for the tamsulosin group (-14.6/-7.5mmHg). However, the average BP change was not different in both group (-12.4/-9.1mmHg in the doxazosin group and -11.3/-6.4mmHg in the tamsulosin group) following a single dose of 20mg vardenafil. The higher the BP was at baseline, the more the reduction in BP was in both the doxazosin and tamsulosin groups. Two patients of tamsulosin showed a sitting systolic BP <85mmHg, but they didn't experience dizziness.

    Conclusions

    We recommend starting Vardenafil treatment in the background of chronic α1 blocker therapy, including tamsulosin, with a low dose and to increase the dose by monitoring the BP, particularly for the patients with hypertension.

    Keywords
    Doxazosin; Tamsulosin; Vardenafil; Blood pressure

    Tables

    Table 1
    Clinical characteristics of the patients (n=90)

    Table 2
    Changes of blood pressure (BP) by a single dose of vardenafil 20mg from baseline following repeated doxazosin 4mg or tamsulosin 0.2mg therapy of 30 days

    Table 3
    The patients with a significant change of blood pressure by a single dose of vardenafil 20mg from baseline following repeated doxazosin 4mg or tamsulosin 0.2mg therapy for 30 days

    Table 4
    Blood pressure by a single dose of vardenafil 20mg from baseline following repeated doxazosin 4mg or tamsulosin 0.2mg therapy for 30 days in normotensive, prehypertensive and hypertensive patients

    References

      1. Cha JS, Park JK. Association between lower urinary tract symptoms and erectile dysfunction. Korean J Urol 2005;46:1023–1027.
      1. Burchardt M, Burchardt T, Baer L, Kiss AJ, Pawar RV, Shabsigh A, et al. Hypertension is associated with severe erectile dysfunction. J Urol 2000;164:1188–1191.
      1. McVary KT. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 2005;47:838–845.
      1. McVary KT, McKenna KF. The relationship between erectile dysfunction and lower urinary tract symptoms: epidemiological, clinical, and basic science evidence. Curr Urol Rep 2004;5:251–257.
      1. van Moorselaar RJ, Hartung R, Emberton M, Harving N, Matzkin H, Elhilali M, et al. Alfuzosin 10mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. BJU Int 2005;95:603–608.
      1. Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC. Sildenafil influences lower urinary tract symptoms. BJU Int 2002;90:836–839.
      1. Gillenwater JY, Conn RL, Chrysant SG, Roy J, Gaffney M, Ice K, et al. Doxazosin for treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. J Urol 1995;154:110–115.
      1. Kaplan SA, Meade-D'Alisera P, Quinones S, Soldo KA. Doxazosin in physiologically and pharmacologically normotensive men with benign prostatic hyperplasia. Urology 1995;46:512–517.
      1. Nieminen T, Ylitalo R, Koobi T, Ylitalo P, Kahonen M. The vasodilatory effect of alfuzosin and tamsulosin in passive orthostasis: a randomised, double-blind, placebo-controlled study. Eur Urol 2005;47:340–345.
      1. Pomara G, Morelli G, Pomara S, Taddei S, Ghiadoni L, Dinelli N, et al. Cardiovascular parameter changes in patients with erectile dysfunction using PDE-5 inhibitors: a study with sildenafil and vardenafil. J Androl 2004;25:625–629.
      1. Kloner RA. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation 2004;110:3149–3155.
      1. Kostis JB, Jackson G, Rosen R, Barrett-Connor E, Billups K, Burnett AL, et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005;96:313–321.
      1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560–2572.
      1. Fulton B, Wagstaff AJ, Sorkin EM. Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs 1995;49:295–320.
      1. de Mey C. Cardiovascular effects of alpha-blockers used for the treatment of symptomatic BPH: impact on safety and well-being. Eur Urol 1998;34 Suppl 2:18–28.
      1. Mazzu A, Sundaresan P, Xia C. In: Bayer Pharmaceutical data file. 2003. An interaction study to evaluate changes in blood pressure and pulse rate following vardenafil compared to placebo treatment on the background of the alpha-blockers, tamsulosin and terazosin, in separate cohorts of patients with benign prostatic hyperplasia.
      1. Spera P, Dabiri G, Ilson B, Montague T, Patel B, Diringer K. In: Bayer Pharmaceutical data file. 2003. A radnomized, double-blind, placebo-controlled, two-part, three period crossover drug interaction study of vardenafil (10mg and 20mg) and tamsulosin (0.4mg) in healthy males aged 45 to 75 to evaluate changes in blood pressure.
      1. Cases A. Doxazosin in a gastrointestinal therapeutic system formulation. Drugs Today (Barc) 2000;36:679–688.
      1. Chapple CR, Carter P, Christmas TJ, Kirby RS, Bryan J, Milroy EJ, et al. A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Br J Urol 1994;74:50–56.
      1. Fawzy A, Braun K, Lewis GP, Gaffney M, Ice K, Dias N. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 1995;154:105–109.
      1. Kloner RA, Mohan P, Segerson T, Thibonnier M, Norenberg C, Padma-Nathan H. Cardiovascular safety of vardenafil in patients receiving antihypertensive medication: a post-hoc analysis of five placebo-controlled clinical trials. J Am Coll Cardiol 2003;41:276A.
      1. Cheitlin MD, Hutter AM Jr, Brindis RG, Ganz P, Kaul S, Russell RO Jr, et al. ACC/AHA expert concensus document use of sildenafil (Viagra) in patients with cardiovascular disease. J Am Coll Cardiol 1999;33:273–282.
      1. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil. Am J Cardiol 2003;92:37M–46M.
      1. Auerbach SM, Gittelman M, Mazzu A, Cihon F, Sundaresan P, White WB. Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. Urology 2004;64:998–1003.
    MeSH Terms
    Blood Pressure*
    Doxazosin*
    Drug Interactions*
    Erectile Dysfunction*
    Humans
    Hypertension
    Male
    Prostatic Hyperplasia*
    Tamsulosin
    Vardenafil Dihydrochloride
    Metrics
    Share
    Tables
    slide
    slide
    slide
    slide

    1 / 4

    PERMALINK